Provided by Tiger Fintech (Singapore) Pte. Ltd.

HENGRUI PHARMA

55.150
+11.10025.20%
Volume:82.66M
Turnover:4.73B
Market Cap:364.18B
PE:53.23
High:60.500
Open:57.000
Low:55.150
Close:44.050
Loading ...

Company Profile

Company Name:
HENGRUI PHARMA
Exchange:
SEHK
Establishment Date:
1970
Employees:
20238
Office Location:
No. 38, Huanghe Road,Economic and Technological Development Zone,Lianyungang City,Jiangsu Province,China
Zip Code:
222000
Fax:
- -
Introduction:
The company was founded in 1970 and listed on the Shanghai Stock Exchange in 2000. It is an innovative international pharmaceutical enterprise focusing on R&D, production and promotion of high-quality drugs. It focuses on research and development of new drugs in the fields of oncology, metabolic and cardiovascular diseases, immune and respiratory diseases, and neuroscience. It is one of the leading pharmaceutical companies with the most innovative capabilities in China. The company's main business involves R&D, production and sales of pharmaceuticals. Main products: pyrrolidinib maleate tablets, carrilizumab for injection, reverulamide tablets, hetrapopa ethanolamine tablets, iodophorol injections, butorphinol tartrate injections, etc. Corporate honors: “Environmental Exemplary Enterprise” and “Leading Green Development Enterprise” in Jiangsu Province, won the Lianyungang Economic and Technological Development Zone Enterprise “Environmental Protection Quality Award” in 2023, won the honorary title of “First Batch of Sterile Drug Quality Assurance Enterprises” issued by the China Pharmaceutical Quality Management Association, and the honorary title of “Jiangsu Pharmaceutical Industry Excellent Quality Management Enterprise” issued by the Jiangsu Pharmaceutical Quality Management Association; the company's “Young Eagle QC Group” and “Yuanzhi QC Group” were rated as Jiangsu Pharmaceutical Industry Quality Management (QC) Excellent Exchange Group and Jiangsu “Green Development Leader” Company” etc.